With origins in the 1950s, Carter BloodCare is one of Texas' largest blood centers, providing 300,000 units of life-saving blood and blood components to patients in North, Central, and East Texas annually.
Step-by-step instructions on how to properly label a patient sample for blood bank testing. [embed]https://youtu.be/Z7GGyOghKfI[/embed]Read More
by W. Crews, M.D., Medical Director of Laboratory Services, Carter BloodCare Molecular genotyping for red blood cell (RBC) antigens has become routinely used for some blood donors and certain patient populations (patients with hemoglobinopathies, recently transfused patients, patients with warm autoantibodies or multiple alloantibodies, for example). In contrast, molecular RHD genotyping for patients with a known…Read More
by W. Crews, M.D., Medical Director of Laboratory Services, Carter BloodCare When DARZALEX® (daratumumab or DARA) was approved by the FDA in November 2015, the transfusion service/blood banking community was quickly front and center with the newest monoclonal antibody treatment. Shortly after receiving FDA approval, it was discovered that DARA caused interference with the antibody screen…Read More
by G. Paranjape, M.D., Medical Director of Clinical Services, Carter BloodCare Zika virus (ZIKV) is a member of the Flaviviridae group and has been known to cause infection since 1953. It is transmitted to humans primarily by the Aedes aegypti mosquito, but it may also be transmitted by the Aedes albopictus mosquito. Cases of intrauterine, perinatal,…Read More
by T. Nishimoto, M.D., Medical Director of Clinical Apheresis Services, Carter BloodCare The American Society for Apheresis (ASFA) released the Seventh Edition of the Guidelines on the Use of Therapeutic Apheresis in Clinical Practice in the Journal of Clinical Apheresis (JCA) in June 2016. The JCA Seventh Edition still contains the ASFA categories and grading system…Read More